Ayako Suzuki

Duke University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (14)

Background and Aims: Older age increases susceptibility to metabolic dysfunction-associated steatotic liver disease (MASLD) but whether it impacts response to therapies, and how the therapies impact regulators of biological aging, are poorly understood. Statins inhibit the mevalonate pathway to block cholesterol biosynthesis and are widely used in MASLD patients to reduce cardiovascular disease. Whether statins prevent progression to cirrhosis is under investigation. However, the molecular effects of statins in human liver, particularly in the context of aging, remain poorly defined. Approach and Results: We analyzed liver transcriptomes and matched clinical data from 368 adults enrolled in the Duke MASLD Biorepository with a focus on age-dependent responses and the interplay between senescence and ferroptosis, a regulated death process that is constrained by the mevalonate pathway. Serum ALT, AST, and LDL cholesterol levels were lower in statin users of both sexes, particularly among older individuals. Transcriptome analyses revealed that statin use strongly associated with suppression of senescence-related pathways. Statin use also associated with increased activation of pathways linked to ferroptosis. Both responses persisted after propensity score matching to control for clinical confounders and were validated in an independent obese cohort. Conclusions: Age-dependent transcriptional remodeling in the liver differs in statin users and non-users. Pathways involved in senescence are suppressed while those that promote ferroptosis are induced in statin users. These results suggest that statins may suppress biological aging in MASLD by acting as senolytics and highlight the complex, context-specific roles of senescence in liver adaptation and remodeling.

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

The Human BioMolecular Atlas Program (HuBMAP) aims to construct a 3D Human Reference Atlas (HRA) of the healthy adult body. Experts from 20+ consortia collaborate to develop a Common Coordinate Framework (CCF), knowledge graphs and tools that describe the multiscale structure of the human body (from organs and tissues down to cells, genes and biomarkers) and to use the HRA to characterize changes that occur with aging, disease and other perturbations. HRA v.2.0 covers 4,499 unique anatomical structures, 1,195 cell types and 2,089 biomarkers (such as genes, proteins and lipids) from 33 ASCT+B tables and 65 3D Reference Objects linked to ontologies. New experimental data can be mapped into the HRA using (1) cell type annotation tools (for example, Azimuth), (2) validated antibody panels or (3) by registering tissue data spatially. This paper describes HRA user stories, terminology, data formats, ontology validation, unified analysis workflows, user interfaces, instructional materials, application programming interfaces, flexible hybrid cloud infrastructure and previews atlas usage applications.

Year:

2025

Background and Aims Osteopontin (OPN) promotes the ductular reaction and is a major driver of chronic liver disease (CLD) progression. Although CLD is characterised by the accumulation of inflammatory cells including macrophages around the peri‐portal regions, the influence of OPN on recruitment is unclear. We investigated the role of OPN in cholangiocyte chemokine production and macrophage recruitment by combining in vivo, in vitro, and in silico approaches. Methods The effects of OPN on cholangiocyte chemokine production and macrophage migration were assessed in culture, alongside RNA‐sequencing to identify genes and pathways affected by OPN depletion. Murine liver injury models were used to assess liver chemokine expression and liver macrophage/monocyte recruitment. OPN and chemokine expression were analysed in liver tissue and plasma from biopsy‐proven metabolic dysfunction‐associated alcoholic steatohepatitis (MASH) patients. Results OPN‐knockdown in cholangiocytes reduced chemokine secretion. RNA‐sequencing showed OPN‐related effects clustered around immunity, chemotaxis and chemokine production. Macrophage exposure to cholangiocyte‐conditioned media showed OPN‐supported migration via chemokines chemokine (C‐C motif) ligand (CCL)2, CCL5 and chemokine (C‐X‐C motif) ligand (CXCL)1. These effects were related to NF‐κB signalling. Murine liver fibrosis was accompanied by upregulated liver OPN, CCL2, CCL5 and CXCL1 mRNA, and accumulation of liver cluster of differentiation (CD)11b/F4/80 + CC chemokine receptors (CCR2) high macrophages but treatment with OPN‐specific neutralising aptamers reduced fibrosis, chemokine mRNAs and accumulation of liver CD11b/F4/80 + CCR2 high /lymphocyte antigen 6 complex high inflammatory monocytes. In human MASH, liver OPN correlated with chemokines CCL2 and IL8 in association with portal injury and fibrosis. Plasma OPN, serum CCL2 and IL8 also increased with fibrosis stage. Conclusions OPN promotes cholangiocyte chemokine secretion and the accumulation of pro‐inflammatory monocytes. These data support neutralisation of OPN as an anti‐inflammatory and anti‐fibrotic strategy.

Year:

2025

Background Men are at higher risk for metabolic dysfunction-associated steatotic liver disease (MASLD) with clinically significant fibrosis (CSF) than premenopausal women, but data are lacking in persons with HIV (PWH). The aim of this study was to discover prevalence and severity of MASLD in PWH by sex assigned at birth and menopausal status. Methods We examined participants from the prospective, cross-sectional HIV NASH CRN who had suppressed HIV-1 RNA, self-reported sex assigned at birth and menopause status, and underwent transient elastography (TE). The primary outcome was MASLD (controlled attenuation parameter [CAP] ≥ 263 dB/m, ≥1 cardiometabolic risk factor, Alcohol Use Disorders Identification Test score <8) with CSF (MASLD-CSF, TE Liver Stiffness Measurement ≥ 8 kPa). Results Nine hundred and sixty-four PWH were included: 709 men (73.5%) and 255 women (26.5%) with similar median ages (55.1 and 56.6 years, P-value = .08). The most common race was Black (52%). Women had lower prevalence of MASLD-CSF than men (5.5% vs 10.6%, P = .02). In a multivariable logistic regression model for MASLD-CSF, diabetes (OR 3.26 [95% confidence interval 2.01–5.30], P < .0001), hyperlipidemia (1.97 [1.14–3.39], P = .02), and waist circumference (WC) above sex-specific cutoff (women: 80 cm, men: 94 cm) (4.59 [2.12–9.93], P < .0001) were associated with higher odds of MASLD-CSF, while female sex was associated with lower odds (0.43 [0.23–0.81], P = .01). Variables and effect sizes associated with MASLD-CSF differed among sex/menopause subgroups. Conclusions Female sex was protective against MASLD-CSF in PWH. Men with diabetes, hyperlipidemia, and high WC would be candidates for MASLD screening. Further studies of PWH with women, especially more young women, are needed.

Year:

2025

Year:

2025

Aims Drug‐induced liver injury (DILI) is a major global health concern resulting from adverse reactions to medications, supplements or herbal medicines. The relevance of DILI has grown with an aging population, the rising prevalence of chronic diseases and the increased use of biologics, including checkpoint inhibitors. This article aims to summarise current knowledge on DILI epidemiology and risk factors. Methods This review critically appraises available evidence on DILI frequency, outcomes and risk determinants, focusing on drug properties and non‐genetic host factors that may influence susceptibility. Results DILI incidence varies across populations, with hospitalised patients experiencing notably higher rates than outpatients or the general population. Increased medication use, particularly among older adults and women, may partly explain age‐ and sex‐based disparities in DILI incidence and reporting. Physiological changes associated with aging likely increase susceptibility to DILI in older adults, though further exposure‐based studies are needed for definitive conclusions. Current evidence does not strongly support that women are inherently more susceptible to DILI than men; rather, susceptibility appears to depend on specific drugs. However, once DILI occurs, older age and female sex are associated with greater severity and poorer outcomes. Other less‐studied host‐related risk factors are also discussed based on available evidence. Conclusions This article summarises existing data on DILI frequency, outcomes, drug properties affecting hepatotoxicity and non‐genetic host risk factors while identifying critical knowledge gaps. Addressing these gaps through future research could enhance understanding and support preventive measures.

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2022

Collaborators (25)

Jason Coombes

Assistant Professor

Saint Louis University

UNITED STATES
View details

Bruce Aronow

John J Hutton MD Professor of Computational Biology and Pediatrics

Cincinnati Children’s Research Foundation

UNITED STATES
View details

Jonathan Silverstein

Professor

University of Pittsburgh

UNITED STATES
View details

Leo van Grunsven

Principal Investigator

Vrije Universiteit Brussel

BELGIUM
View details

Sarah Teichmann

University of Cambridge

UNITED KINGDOM
View details

Brijesh Kumar Singh

Assistant Professor

Duke-NUS Medical School

SINGAPORE
View details

Katy Börner

Indiana State University

UNITED STATES
View details

Yang Li

Indiana University School of Medicine

UNITED STATES
View details

Joel Sunshine

Assistant Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Purushothama Rao Tata

Duke University

UNITED STATES
View details

David Umbaugh

Postdoctoral Associate

Duke University

UNITED STATES
View details

Liuyang Wang

Research Associate Professor

Duke University

UNITED STATES
View details

Mark Musen

Professor

Stanford University

UNITED STATES
View details

Shilpa Chokshi

Professor at University of Plymouth

University of Plymouth

UNITED KINGDOM
View details

Cynthia Moylan

Professor of Medicine

Duke University

UNITED STATES
View details

Fusheng Wang

Professor

Stony Brook University

UNITED STATES
View details

Manal Abdelmalek

Professor of Medicine, Director MASLD Clinical Research

Mayo Clinic

UNITED STATES
View details

Audrey Lloyd

Assistant Professor

University of Alabama, Tuscaloosa

UNITED STATES
View details

Jean Fan

Assistant Professor

Johns Hopkins University

UNITED STATES
View details

Timothy Kendall

Chair of Liver Pathology

University of Edinburgh

UNITED KINGDOM
View details

Kuo Du

Assistant Professor

University of Kansas Medical Center

UNITED STATES
View details

Rajesh Kumar Dutta

Research Associate, Senior

Duke University

UNITED STATES
View details

Jeffrey Spraggins

Director

Vanderbilt University Medical Center

UNITED STATES
View details

Andreas Bueckle

Research Lead

Indiana University

UNITED STATES
View details

Gloria Pryhuber

Professor

University of Rochester Medical Center

UNITED STATES
View details